Loading...
XNAS
PRCT
Market cap2.00bUSD
Dec 05, Last price  
35.86USD
1D
1.21%
1Q
-11.85%
IPO
-0.14%
Name

PROCEPT BioRobotics Corp

Chart & Performance

D1W1MN
XNAS:PRCT chart
P/E
P/S
8.93
EPS
Div Yield, %
Shrs. gr., 5y
3.80%
Rev. gr., 5y
105.21%
Revenues
224m
+64.84%
6,169,0007,717,00034,473,00075,014,000136,191,000224,498,000
Net income
-91m
L-13.68%
-42,653,000-58,255,000-62,384,000-93,584,000-105,897,000-91,413,000
CFO
-99m
L-8.14%
-43,818,000-48,343,000-57,334,000-80,382,000-108,003,000-99,213,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally-invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). The company also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. As of December 31, 2021, it had an install base of 130 AquaBeam Robotic Systems worldwide comprising 78 in the United States. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in Redwood City, California.
IPO date
Sep 15, 2021
Employees
428
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT